What is the latest news on UROV?

Quantisnow has not tracked any new filings, ratings or press releases for UROV in the last 30 days. The most recent wire item was published on March 7, 2022.

Where does UROV stock trade?

Urovant Sciences Ltd. (UROV) is listed on NASDAQ.

What sector and industry is UROV in?

Urovant Sciences Ltd. operates in the Health Care sector, Major Pharmaceuticals industry.

When did Urovant Sciences Ltd. go public?

Urovant Sciences Ltd. (UROV) completed its IPO in 2018.

What companies are similar to UROV?

Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare UROV side-by-side with any of them on Quantisnow.

How can I track UROV on Quantisnow?

Quantisnow aggregates Urovant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UROV to receive live email and push alerts on every new disclosure.

UROV

Urovant Sciences Ltd. · NASDAQ

Follow + get alerts

SectorHealth Care IndustryMajor PharmaceuticalsIPO2018

Urovant Sciences Ltd. (UROV) is a Major Pharmaceuticals company listed on NASDAQ. There were no new wire items for UROV in the last 30 days. The most recent was published Mar 7, 2022.

Latest news

25 items

1713dPR
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies. "URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency
1790dPR
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urination), urinary urgency episodes, and urge urinary incontinence episodes vs. placebo. This analysis supports that the statistically significant reductions in clinical endpoints seen in the EMPOWUR trial are meaningful to patients. Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Advances in Therapy has published patient-perception data supporting clinica
1832dPR
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Data from a dedicated ambulatory blood pressure study showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved overactive bladder (OAB) therapy, GEMTESA® (vibegron) in the U.S. The peer-reviewed publication is currently available online and the print article is scheduled to be published in an upcoming issue of the journal. In a dedicated, double-blind, placebo-controlled ambulat
2046dSEC
SEC Form 15-12B filed by Urovant Sciences Ltd.
15-12B - Urovant Sciences Ltd. (0001740547) (Filer)
2054dSEC
SEC Form EFFECT filed by Urovant Sciences Ltd.
EFFECT - Urovant Sciences Ltd. (0001740547) (Filer)
2054dINSIDER
SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Pierre Legault disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Shares (8,385 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Walt Johnston disposed to the issuer $0 worth of Common Shares (109,139 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: S Myrtle Potter disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2054dINSIDER
SEC Form 4: Christine Ocampo disposed to the issuer $0 worth of Common Shares (78,781 units at $0.00), decreasing direct ownership by 100% to 0 units
4 - Urovant Sciences Ltd. (0001740547) (Issuer)
2055d13D/G
SEC Form SC 13D/A filed by Urovant Sciences Ltd.
SC 13D/A - Urovant Sciences Ltd. (0001740547) (Subject)
2056dSEC
SEC Form SC 13E3/A filed by Urovant Sciences Ltd.
SC 13E3/A - Urovant Sciences Ltd. (0001740547) (Subject)
2056dSEC
SEC Form S-8 POS filed by Urovant Sciences Ltd.
S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
2056dSEC
SEC Form S-8 POS filed by Urovant Sciences Ltd.
S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
2056dSEC
SEC Form S-8 POS filed by Urovant Sciences Ltd.
S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
2056dSEC
SEC Form POS AM filed by Urovant Sciences Ltd.
POS AM - Urovant Sciences Ltd. (0001740547) (Filer)
2056dSEC
SEC Form 25-NSE filed by Urovant Sciences Ltd.
25-NSE - Urovant Sciences Ltd. (0001740547) (Subject)
2056dSEC
Urovant Sciences Ltd. filed SEC Form 8-K: Completion Of Acquisition Or Dispositive Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws, Other Events, Financial Statements And Exhibits
8-K - Urovant Sciences Ltd. (0001740547) (Filer)
2056dPR
Sumitovant Biopharma Completes Acquisition of Urovant Sciences Sumitovant Biopharma
NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of the merger in which Sumitovant has acquired all outstanding shares of Urovant Sciences. The merger agreement and the merger were approved on March 23, 2021 by the affirmative vote of holders of a majority of Urovant’s outstanding shares, and by holders of a majority of Urovant's outstanding shares that are not held by Sumitovant. “As with other companies in the Sumitovant family, Urovant will be privately held and maintain its distinct culture and focus while benefiting from the strateg
2061dSEC
SEC Form 8-K filed by Urovant Sciences Ltd.
8-K - Urovant Sciences Ltd. (0001740547) (Filer)

UROV FAQ

6 questions

What is the latest news on UROV?
Quantisnow has not tracked any new filings, ratings or press releases for UROV in the last 30 days. The most recent wire item was published on March 7, 2022.
Where does UROV stock trade?
Urovant Sciences Ltd. (UROV) is listed on NASDAQ.
What sector and industry is UROV in?
Urovant Sciences Ltd. operates in the Health Care sector, Major Pharmaceuticals industry.
When did Urovant Sciences Ltd. go public?
Urovant Sciences Ltd. (UROV) completed its IPO in 2018.
What companies are similar to UROV?
Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare UROV side-by-side with any of them on Quantisnow.
How can I track UROV on Quantisnow?
Quantisnow aggregates Urovant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UROV to receive live email and push alerts on every new disclosure.